Back to News
Market Impact: 0.15
CNMD Crosses Above Average Analyst Target
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
CONMED shares traded at $46.95, exceeding the average 12-month analyst price target of $46.43 by $0.52, or roughly 1.1%. The move above consensus target may prompt analysts to reassess valuation assumptions or revise price targets, but the article provides no updated ratings, estimates, or company fundamentals.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
CNMD0.20
More News
- DST Global Advisors, 10% owner, sells $109.3m Chime stock
- DST Global Advisors sells $109.3m in Chime Financial shares
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
- Snowflake SVP Vivek Raghunathan sells $1.23m in company stock
- AI-Fueled Profit Growth Set to Flow Through Every S&P 500 Sector
- Japan has a problematic age gap: 100,000-plus residents are over 100 and the pension system is buckling